Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACRS Aclaris Therapeutics

Market Closed 12-12 16:00:00 EST

3.25

-0.11

-3.27%

盘后3.25

+0.000.00%

19:22 EST

High3.41	Low3.25	Vol1.65M
Open3.41	D1 Closing3.36	Amplitude4.96%
Mkt Cap352.12M	Tradable Cap236.12M	Total Shares108.35M
T/O5.46M	T/O Rate2.27%	Tradable Shares72.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACRS","market":"US","secType":"STK","nameCN":"Aclaris Therapeutics","latestPrice":3.25,"timestamp":1765573200000,"preClose":3.36,"halted":0,"volume":1647414,"hourTrading":{"tag":"盘后","latestPrice":3.25,"preClose":3.25,"latestTime":"19:22 EST","volume":697776,"amount":2267770.7092,"timestamp":1765585359228},"delay":0,"floatShares":72651442,"shares":108345239,"eps":-1.224907,"marketStatus":"Market Closed","change":-0.11,"latestTime":"12-12 16:00:00 EST","open":3.41,"high":3.4117,"low":3.245,"amount":5457897.9029502,"amplitude":0.049613,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.224907,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1444190400000,"exchange":"NASDAQ","adjPreClose":3.36,"preHourTrading":{"tag":"盘前","latestPrice":3.37,"preClose":3.36,"latestTime":"09:20 EST","volume":1319,"amount":4446.3578373,"timestamp":1765549210676},"postHourTrading":{"tag":"盘后","latestPrice":3.25,"preClose":3.25,"latestTime":"19:22 EST","volume":697776,"amount":2267770.7092,"timestamp":1765585359228},"volumeRatio":1.0906796346117378,"impliedVol":1.3476,"impliedVolPercentile":0.536},"requestUrl":"/m/hq/s/ACRS","defaultTab":"news","newsList":[{"id":"2586278432","title":"Aclaris Therapeutics management to meet with Cantor","url":"https://stock-news.laohu8.com/highlight/detail?id=2586278432","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586278432?lang=en_us&edition=fundamental","pubTime":"2025-11-28 03:35","pubTimestamp":1764272107,"startTime":"0","endTime":"0","summary":"Group Dinner Meeting to be held in New York on December 1 at 6 pm hosted by Cantor. Published first on TheFly – the ultimate source for real-time, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-management-to-meet-with-cantor-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-management-to-meet-with-cantor-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2584267829","title":"Aclaris Therapeutics Q3 Net Income USD -14.614 Million Vs. IBES Estimate USD -15.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584267829","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584267829?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:52","pubTimestamp":1763571139,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Aclaris Therapeutics Q3 revenue USD 3.299 million vs. IBES estimate USD 1.59 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202511:59:46.573 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2J3cl5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2581725067","title":"Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $3.299M Beat $1.405M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581725067","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581725067?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:24","pubTimestamp":1762431898,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 11.11 percent. This is a 9.09 percent decrease over losses of $(0.11) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48682834/aclaris-therapeutics-q3-eps-0-12-beats-0-14-estimate-sales-3-299m-beat-1-405m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"gpt_icon":0},{"id":"2581218062","title":"Aclaris Therapeutics Q3 revenue beats estimates, net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2581218062","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581218062?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:07","pubTimestamp":1762430862,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Q3 revenue beats estimates, net loss narrowsOverviewAclaris Q3 revenue beats analyst expectations despite a year-over-year declineNet loss for Q3 smaller than expected, reflecting","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0JM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2581627870","title":"Aclaris Therapeutics reports third quarter 2025 financial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581627870","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581627870?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:05","pubTimestamp":1762430744,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc. reported cash, cash equivalents, and marketable securities of $167.2 million as of September 30, 2025, down from $203.9 million at year-end 2024. The company noted decreases in revenue for the quarter and nine months ended September 30, 2025, mainly due to larger milestones achieved under the Sun Pharma license agreement and higher licensing revenue from the Eli Lilly agreement in the prior year. Research and development expenses were $13.0 million for the quarter and $36.1 million for the nine months ended September 30, 2025, compared to $6.0 million and $24.6 million in the previous year periods, driven by increased manufacturing costs, preclinical development, and clinical activities. Major business developments included positive results from the Phase 2a trial of ITK/JAK3 inhibitor ATI-2138 in atopic dermatitis, with a Phase 2 trial in another indication anticipated in the first half of 2026, and continued progress in trials for Bosakitug  and ATI-052. The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL5KmywM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837136.USD","SG9999014898.SGD","LU0882574055.USD","LU2168564222.USD","LU0106261372.USD","SGXZ57979304.SGD","LU0471298777.SGD","LU1057294990.SGD","LU1069344957.HKD","SGXZ99366536.SGD","LU0006306889.USD","LU0096364046.USD","SG9999001176.USD","LU1061106388.HKD","LU0823434740.USD","LU2087625088.SGD","LU2471134796.USD","LU1868837300.USD","LU2750360641.GBP","LU1720051108.HKD","LU0354030438.USD","LU1814569148.SGD","LU2264538146.SGD","LU0114720955.EUR","LU1548497426.USD","LU2168564495.EUR","LU1868836757.USD","SG9999015952.SGD","SG9999014906.USD","BK4599","LU0109394709.USD","LU2471134523.USD","SG9999018857.SGD","LU0354030511.USD","LU0672654240.SGD","IE0002141913.USD","SG9999018865.SGD","SG9999015945.SGD","BK4007","LU0823434583.USD","LU1868836591.USD","LU0943347566.SGD","LU0234572021.USD","IE00BWXC8680.SGD","LU1868836914.USD","LU2168564065.EUR","LU2106854487.HKD","LU2750360997.AUD","ACRS"],"gpt_icon":1},{"id":"2581064115","title":"BRIEF-Aclaris Therapeutics Q3 Net Income USD -14.614 Million Vs. IBES Estimate USD -15.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581064115","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581064115?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:59","pubTimestamp":1762430386,"startTime":"0","endTime":"0","summary":"BRIEF-Aclaris Therapeutics Q3 Net Income USD -14.614 Million Vs. IBES Estimate USD -15.8 Million\n\n\nNov 06 (Reuters) - Aclaris Therapeutics Q3 revenue USD 3.299 million vs. IBES estimate USD 1.59 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLX175764:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2580997174","title":"Aclaris Therapeutics Inc  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580997174","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580997174?lang=en_us&edition=fundamental","pubTime":"2025-11-01 00:05","pubTimestamp":1761926741,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc  expected to post a loss of13cents a share - Earnings Preview Aclaris Therapeutics Inc ACRS.OQ ACRS.O is expected to  show a fall in quarterly revenue when it reports  results","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nL8N3WC1VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2579903587","title":"Aclaris Therapeutics to Participate in Three November Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2579903587","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579903587?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:30","pubTimestamp":1761737400,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Oct.  29, 2025  (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflamma","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176312/37216/en/Aclaris-Therapeutics-to-Participate-in-Three-November-Healthcare-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029874061.USD","LABU","XLV","BK4007","BK4588","BK4581","HCSG","BK4137","LU0128526141.USD","BK4585","XBI","ACRS"],"gpt_icon":0},{"id":"2576562768","title":"Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2576562768","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576562768?lang=en_us&edition=fundamental","pubTime":"2025-10-20 19:49","pubTimestamp":1760960940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ACRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 20, 2025 07:49 ET (11:49 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"gpt_icon":0},{"id":"2575671391","title":"Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Aclaris Therapeutics (ACRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2575671391","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575671391?lang=en_us&edition=fundamental","pubTime":"2025-10-16 16:10","pubTimestamp":1760602211,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY – Research Report) and Acl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-and-aclaris-therapeutics-acrs-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-and-aclaris-therapeutics-acrs-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756168.USD","LU1571399168.USD","LU1323610961.USD","LU0868494617.USD","LU1868836591.USD","LU2125154935.USD","BK4007","LU1291159041.SGD","LU0321505868.SGD","BMY","LU1074936037.SGD","LU0096364046.USD","LU0029874061.USD","LU2242652126.USD","LU1718418525.SGD","BK4588","IE00BSNM7G36.USD","LU1032466523.USD","LU1868836914.USD","LU1868837300.USD","BK4532","LU1670710661.SGD","LU1093756325.SGD","BK4581","HCSG","LABU","ACRS","LU0225771236.USD","LU1261432733.SGD","LU2242646821.SGD","LU0456855351.SGD","XLV","LU0225284248.USD","LU0306806265.USD","LU0882574055.USD","LU0128526141.USD","LU0321505439.SGD","LU0267386448.USD","LU0306807586.USD","XBI","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU1868836757.USD","BK4585","IE0009355771.USD","LU0114720955.EUR","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU0237698245.USD","LU1585245621.USD"],"gpt_icon":0},{"id":"2575739203","title":"Cantor Fitzgerald Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2575739203","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575739203?lang=en_us&edition=fundamental","pubTime":"2025-10-15 23:15","pubTimestamp":1760541332,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Buy rating on Aclaris Therapeutics today. The company’s shares opened today at $1.85. Agrawa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-its-buy-rating-for-aclaris-therapeutics-acrs-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-its-buy-rating-for-aclaris-therapeutics-acrs-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS"],"gpt_icon":0},{"id":"2575929282","title":"Aclaris Therapeutics Hosts R&D Day for Innovations","url":"https://stock-news.laohu8.com/highlight/detail?id=2575929282","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575929282?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:36","pubTimestamp":1760441791,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics ( ($ACRS) ) has shared an update. On October 14, 2025, Aclaris Therapeutics will hold an R&D Day to showcase their innovative ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aclaris-therapeutics-hosts-rd-day-for-innovations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aclaris-therapeutics-hosts-rd-day-for-innovations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2571443341","title":"Aclaris Therapeutics to host R&D Day on October 14","url":"https://stock-news.laohu8.com/highlight/detail?id=2571443341","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571443341?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:15","pubTimestamp":1759230937,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics (ACRS) will host it’s 2025 R&D Day in Midtown, New York on Tuesday, October 14, 2025 at 8:00 AM ET to discuss the Company’s pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-to-host-rd-day-on-october-14-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aclaris-therapeutics-to-host-rd-day-on-october-14-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACRS","BK4007"],"gpt_icon":0},{"id":"2571415253","title":"Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2571415253","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571415253?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:00","pubTimestamp":1759230000,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Sept.  30, 2025  (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflamm","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/30/3158436/37216/en/Aclaris-Therapeutics-to-Host-In-Person-and-Webcast-R-D-Day-Patient-Focused-Innovation-Addressing-Gaps-in-Immuno-Inflammatory-Markets-in-New-York-on-October-14-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","HST","BK4181","ACRS","BK4585","BK4588","BK4007"],"gpt_icon":0},{"id":"2566699154","title":"Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2566699154","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566699154?lang=en_us&edition=fundamental","pubTime":"2025-09-09 19:00","pubTimestamp":1757415600,"startTime":"0","endTime":"0","summary":"- Late Breaking Abstract to Present Additional Data from Aclaris’ Phase 2a Trial of ATI-2138 in Atopic Dermatitis- WAYNE, Pa., Sept.  09, 2025  (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/09/3146753/37216/en/Aclaris-Therapeutics-Announces-Late-Breaking-Abstract-and-Oral-Presentation-On-ATI-2138-Phase-2a-Results-at-the-2025-European-Academy-of-Dermatology-and-Venereology-EADV-Congress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","LU1878469433.USD","IE00B66KJ199.SGD","BK4007","AD","BK4187","IE00B19Z4B17.USD","BK4006","ATI","BK4132","LU2065731478.USD","IE0031619046.USD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2562665746","title":"Aclaris Therapeutics to Participate in Two September Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2562665746","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562665746?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:00","pubTimestamp":1756296000,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., Aug.  27, 2025  (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflamma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/27/3139973/37216/en/Aclaris-Therapeutics-to-Participate-in-Two-September-Healthcare-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS","HCSG","BK4137"],"gpt_icon":0},{"id":"2557678560","title":"Aclaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2557678560","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557678560?lang=en_us&edition=fundamental","pubTime":"2025-08-08 00:41","pubTimestamp":1754584878,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryAclaris Therapeutics Inc ACRS.OQ reported a quarterly adjusted loss of 13 cents per share for the quarter ended","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nL8N3TZ2FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"gpt_icon":0},{"id":"2557655781","title":"Aclaris Therapeutics Q2 EPS $(0.13) Beats $(0.14) Estimate, Sales $1.777M Beat $1.435M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557655781","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557655781?lang=en_us&edition=fundamental","pubTime":"2025-08-07 19:19","pubTimestamp":1754565596,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Q2 EPS $(0.13) Beats $(0.14) Estimate, Sales $1.777M Beat $1.435M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46957820/aclaris-therapeutics-q2-eps-0-13-beats-0-14-estimate-sales-1-777m-beat-1-435m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"gpt_icon":0},{"id":"2557314170","title":"Aclaris Therapeutics Inc. Files Initial Beneficial Ownership Statement for Chief Scientific Officer Roland Kolbeck","url":"https://stock-news.laohu8.com/highlight/detail?id=2557314170","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557314170?lang=en_us&edition=fundamental","pubTime":"2025-08-06 04:32","pubTimestamp":1754425931,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc. has filed an initial statement of beneficial ownership with the United States Securities and Exchange Commission. The filing lists Roland Wilhelm Kolbeck as the beneficial owner, who serves as the Chief Scientific Officer of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nNDL8vdXMk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ACRS"],"gpt_icon":0},{"id":"2556108814","title":"Aclaris Therapeutics Inc  expected to post a loss of 13 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2556108814","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556108814?lang=en_us&edition=fundamental","pubTime":"2025-08-01 22:28","pubTimestamp":1754058500,"startTime":"0","endTime":"0","summary":"Aclaris Therapeutics Inc  expected to post a loss of13cents a share - Earnings Preview Aclaris Therapeutics Inc ACRS.OQ ACRS.O is expected to  show a fall in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nL8N3TT24T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aclaristx.com","stockEarnings":[{"period":"1week","weight":0.113},{"period":"1month","weight":0.3485},{"period":"3month","weight":0.6667},{"period":"6month","weight":1.2109},{"period":"1year","weight":-0.0061},{"period":"ytd","weight":0.3105}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.3,"avgChangeRate":0.143486},{"month":2,"riseRate":0.4,"avgChangeRate":-0.024357},{"month":3,"riseRate":0.4,"avgChangeRate":-0.054834},{"month":4,"riseRate":0.4,"avgChangeRate":-0.010072},{"month":5,"riseRate":0.5,"avgChangeRate":-0.043272},{"month":6,"riseRate":0.6,"avgChangeRate":-0.004956},{"month":7,"riseRate":0.6,"avgChangeRate":0.009999},{"month":8,"riseRate":0.5,"avgChangeRate":-0.019617},{"month":9,"riseRate":0.4,"avgChangeRate":0.026634},{"month":10,"riseRate":0.4,"avgChangeRate":0.132278},{"month":11,"riseRate":0.363636,"avgChangeRate":0.075295},{"month":12,"riseRate":0.727273,"avgChangeRate":0.100145}],"exchange":"NASDAQ","name":"Aclaris Therapeutics","nameEN":"Aclaris Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aclaris Therapeutics,ACRS,Aclaris Therapeutics股票,Aclaris Therapeutics股票老虎,Aclaris Therapeutics股票老虎国际,Aclaris Therapeutics行情,Aclaris Therapeutics股票行情,Aclaris Therapeutics股价,Aclaris Therapeutics股市,Aclaris Therapeutics股票价格,Aclaris Therapeutics股票交易,Aclaris Therapeutics股票购买,Aclaris Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aclaris Therapeutics(ACRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aclaris Therapeutics(ACRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction